Skip to main content

Odomzo Side Effects

Generic name: sonidegib

Medically reviewed by Last updated on Jun 29, 2023.

Note: This document contains side effect information about sonidegib. Some dosage forms listed on this page may not apply to the brand name Odomzo.

Applies to sonidegib: oral capsule.


Oral route (Capsule)

Use of sonidegib during pregnancy can cause embryofetal death or severe birth defects. Verify pregnancy status prior to initiating treatment and advise females of reproductive potential to use adequate contraception during treatment and for at least 20 months after discontinuation. Male patients with a female partner of reproductive potential must be advised to use adequate contraception during treatment for at least 8 months after discontinuation.

Serious side effects of Odomzo

Along with its needed effects, sonidegib (the active ingredient contained in Odomzo) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking sonidegib:

More common


Other side effects of Odomzo

Some side effects of sonidegib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to sonidegib: oral capsule.


Very common (10% or more): Increased serum creatinine (92%), increased serum creatinine kinase (61%), muscle spasms (54%), musculoskeletal pain (32%), myalgia (19%)

Uncommon (0.1% to 1%): Rhabdomyolysis[Ref]

75% of patients with increased serum creatinine had levels that remained within normal range.[Ref]


Very common (10% or more): Alopecia (53%), pruritus (10%)

Common (1% to 10%): Rash, abnormal hair growth[Ref]


Very common (10% or more): Hyperglycemia (51%), dysgeusia (46%), decreased weight (30%), decreased appetite (23%)

Common (1% to 10%): Dehydration[Ref]

Nervous system

Very common (10% or more): Dysgeusia (46%), headache (15%)[Ref]


Very common (10% or more): Increased lipase (43%), nausea (39%), diarrhea (32%), abdominal pain (18%), increased amylase (16%), vomiting (11%)

Common (1% to 10%): Dyspepsia, constipation, GI reflux[Ref]


Very common (10% or more): Fatigue (41%), pain (14%)[Ref]


Very common (10% or more): Anemia (32%), lymphopenia (28%)[Ref]


Very common (10% or more): Increased ALT (19%), increased AST (19%)[Ref]


Frequency not reported: Amenorrhea[Ref]

Frequently asked questions


1. Cerner Multum, Inc. "Australian Product Information."

2. (2015) "Product Information. Odomzo (sonidegib)." Novartis Pharmaceuticals

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.